<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201219049755N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-11</date_registration>
      <primary_sponsor>Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of Integrated Treatment of Family Focused Therapy (FFT) and Social Cognition and Interaction Training (SCIT) In  Patients with Bipolar Type 1</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of The Effect of Integrated Treatment of Family Focused Therapy (FFT) and Social Cognition and Interaction Training (SCIT) on the Signs and Symptoms, Interpersonal Relationships, Relapse and Quality of Life among Patients with Bipolar Type 1 and study of the effective elements of these two therapeutic approaches.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-14</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>75</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54454</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Prevention, Other design features: This study included a review of the combined effectiveness of the two treatments. In family-centered therapy, the presence of the patient's primary caregiver is essential for education. But the treatment of social cognition and interaction training will be only on patients.  to evaluate the effective elements of the two therapies will be used of  researcher-made checklists that will be completed  by a researcher colleague of the patient's family members. Based on this, we will develop an integrated protocol according to the effective components of the two treatments  in accordance with Iranian culture, Randomization description: The method of random allocation will be drawing a number as a lottery container containing 25 balls for the experimental group 1, 25 balls for the experimental group 2 and 25 balls for the control group. Then the balls will be randomly taken out without replacement from the container and the sequence will be written on a piece of paper. The first number will be assigned to experimental group 1, the second one to experimental group 2 and the third one to control group, and this process will be continued until the last number.Allocation concealment will be also done only in data analysis.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Bipolar disorder type 1.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: This group ,in addition to receiving  medication, will be received 15 sessions of family-focused treatment with their primary  caregivers  twice a week. After the Completion of the intervention  and a 2 week wash out period, patients will be received social cognition and interaction training twice a week. Intervention 2: Intervention group 2: This group ,in addition to medication, will be received 15 sessions of social cognition and interaction training twice a week. After Completion of  the intervention and  2-week wash out  period, patients will be received family-focused treatment twice a week with their primary caregiver. Intervention 3: Control group: This group  will be received medication.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information of primary and secondary consequences will be shared.

When:
3 months after the results are published.

To whom:
Academic institutions

Conditions:
people  intend to repeat the protocol in psychiatric hospitals.

Where to obtain:
By email address: ma.yosefi@uswr.ac.ir

How to obtain:
2 to 3 months

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Maryam Yosefi Tabas</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Psychology; University of Social Welfare and Rehabilitation Sciences; Kodakyar avenue; Daneshjo boulevard; Evin</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985713871</zip>
        <telephone>+98 21 2218 0045</telephone>
        <email>ymary9940@gmail.com</email>
        <affiliation>University of social welfare and rehabilitation sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fereshte Momeni</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Psychology; University of Social Welfare and Rehabilitation Sciences; Kodakyar avenue; Daneshjo boulevard; Evin</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985713871</zip>
        <telephone>+98 21 2218 0045</telephone>
        <email>momenipsy@gmail.com</email>
        <affiliation>University of social welfare and rehabilitation sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Bipolar disorder type 1 has been diagnosed by a psychiatrist
Having a score between 14 -18 in the Cognitive complaints in bipolar disorder rating assessment (COBRA)
Don't having more than 3 recurrences
At least had a high school education
Having a score below 9 had  in the Young Mania Scale
Consent must be Obtained from patient's primary caregiver for participating in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Had a history of alcohol and substance abuse.
Had a history of brain injury.
Had a mental disorder other than the main diagnosis.
Had a severe personality disorder (diagnosed by a psychiatrist)
Had simultaneous  visits to psychological clinics for psychological treatment.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F31.77</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Bipolar disorder, in partial remission, most recent episode mixed</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: This group ,in addition to receiving  medication, will be received 15 sessions of family-focused treatment with their primary  caregivers  twice a week. After the Completion of the intervention  and a 2 week wash out period, patients will be received social cognition and interaction training twice a week.</i_keyword>
      <i_keyword>Intervention group 2: This group ,in addition to medication, will be received 15 sessions of social cognition and interaction training twice a week. After Completion of  the intervention and  2-week wash out  period, patients will be received family-focused treatment twice a week with their primary caregiver.</i_keyword>
      <i_keyword>Control group: This group  will be received medication.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Score of depression  in Beck Depression Inventory. Timepoint: Before the intervention, after the completion of the first intervention, after the completion of the second intervention, follow-up. Method of measurement: Beck Depression Inventory.</prim_outcome>
      <prim_outcome>Score of quality of life of  patients in  Quality of Life Questionnaire. Timepoint: Before intervention, after completion of the first intervention, after completion of the second intervention, follow-up. Method of measurement: Quality of Life Questionnaire (WHO-QOL-BREF).</prim_outcome>
      <prim_outcome>Score of mania  in Young Mania Questionnaire. Timepoint: Before the intervention, after the completion of the first intervention, after the completion of the second intervention, follow-up. Method of measurement: Young Mania Questionnaire.</prim_outcome>
      <prim_outcome>Score of  Interpersonal relations in social performance questionnaire. Timepoint: Before the intervention, after the completion of the first intervention, after the completion of the second intervention, follow-up. Method of measurement: social performance questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Relapse. Timepoint: Before intervention, after completion of the first intervention, after completion of the second intervention, follow-up. Method of measurement: scores above 20 in  the Beck Depression and Young Mania Inventory.</sec_outcome>
      <sec_outcome>Social performance. Timepoint: Before intervention, after completion of the first intervention, after completion of the second intervention, follow-up. Method of measurement: Social Performance Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-14</approval_date>
        <contact_name>Ethics committee of Tehran University of Social Welfare and Rehabilitation Science</contact_name>
        <contact_address>Kodakyar Ave,  Daneshjo Blvd, Evin Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
